CC
CTIC

Caxton Corporation’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Caxton Corporation’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,239,300
Closed -$5.55M – 52
2021
Q4 		$5.55M Buy
2,239,300
+1,239,300
+124% +$3.03M 4.54% 9
2021
Q3 		$2.95M Sell
1,000,000
-1,314,533
-57% -$3.58M 2.39% 10
2021
Q2 		$5.79M Sell
2,314,533
-200,114
-8% -$480K 3.96% 10
2021
Q1 		$7.32M Sell
2,514,647
-1,235,243
-33% -$4.03M 4.75% 8
2020
Q4 		$12.1M Sell
3,749,890
-563,727
-13% -$1.88M 7.53% 4
2020
Q3 		$9.27M Buy
4,313,617
+3,694,157
+596% +$4.72M 8.74% 4
2020
Q2 		$719K Buy
619,460
+2,765
+0.4% +$2.92K 0.76% 12
2020
Q1 		$567K Buy
616,695
+291,085
+89% +$334K 0.62% 10
2019
Q4 		$514K Buy
325,610
+425
+0.1% +$403 0.5% 14
2019
Q3 		$272K Buy
325,185
+733
+0.2% +$559 0.31% 17
2019
Q2 		$279K Buy
324,452
+1,426
+0.4% +$1.32K 0.32% 15
2019
Q1 		$313K Buy
323,026
+199,085
+161% +$210K 0.29% 16
2018
Q4 		$91K Sell
123,941
-73,518
-37% -$121K 0.11% 25
2018
Q3 		$427K Buy
+197,459
New +$489K 0.39% 18

Other funds holding CTIC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caxton Corporation's CTIC Position: Q1 2022 in Review

Caxton Corporation sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2022, closing a stake of 2,239,300 shares — an estimated $5.55M sold.

Caxton Corporation first reported a position in CTIC in Q3 2018 and held it in 14 quarters. The position peaked at $12.1M in Q4 2020. 92 funds tracked by Wall St. Rank hold CTIC as of Q1 2022.

  • Caxton Corporation reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2022 after selling out during the quarter.
  • Caxton Corporation sold 2,239,300 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2022, an estimated $5.55M.
  • Caxton Corporation first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2018 and held it in 14 quarters.
  • Caxton Corporation's CTI BioPharma Corp. (DE) Common Stock position peaked at $12.1M in Q4 2020.
  • 92 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2022.

Based on Caxton Corporation's 13F filing for Q1 2022, filed 16 May 2022.